Thu. 28 Mar 2024, 7:26am ET
Benzinga
Earnings, News
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 45.45 percent increase over losses of $(0.22) per share from the same period last year.